3-MeO-PCMo

3-MeO-PCMo is a dissociative anesthetic drug which is similar in structure to phencyclidine[1][2] and been sold online as a designer drug.[3][4] The inhibitory effect of 3-MeO-PCMo on the reduction in the density of the drebrin clusters by NMDAR stimulation with glutamate acid is lower than that of PCP or 3-MeO-PCP, with IC₅₀ values of 26.67 μM (3-MeO-PCMo), 2.02 μM (PCP) and 1.51 μM (3-MeO-PCP).[5]

3-MeO-PCMo

Legal status
Legal status	UK: Under Psychoactive Substances Act
Identifiers
IUPAC name 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine
CAS Number	138873-80-0
PubChem CID	132605908
ChemSpider	58191437
Chemical and physical data
Formula	C17H25NO2
Molar mass	275.392 g·mol^−1
3D model (JSmol)	Interactive image
SMILES COC1=CC(C2(N3CCOCC3)CCCCC2)=CC=C1
InChI InChI=1S/C17H25NO2/c1-19-16-7-5-6-15(14-16)17(8-3-2-4-9-17)18-10-12-20-13-11-18/h5-7,14H,2-4,8-13H2,1H3 Key:BOGOEDFWPOXWQE-UHFFFAOYSA-N

See also

• Arylcyclohexylamine
• Ketamine
• 3-HO-PCP
• 3-MeO-PCE
• 3-MeO-PCP
• 4-MeO-PCP
• Methoxyketamine

References

1. Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (April 2011). "New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats". Pharmacology, Biochemistry, and Behavior. 98 (2): 227–33. doi:10.1016/j.pbb.2010.12.019. PMID 21215770. S2CID 24650035.
2. Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (March 2020). "4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels". Psychopharmacology. 237 (3): 757–772. doi:10.1007/s00213-019-05412-y. PMID 31828394. S2CID 209169410.
3. Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (February 2018). "Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues". Drug Testing and Analysis. 10 (2): 272–283. doi:10.1002/dta.2213. PMID 28513099.
4. "3-MeO-PCMo". New Synthetic Drugs Database. Archived from the original on 2016-07-03. Retrieved 2016-02-09.
5. Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (September–October 2019). "Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay". Journal of Pharmacological and Toxicological Methods. 99: 106583. doi:10.1016/j.vascn.2019.106583. PMID 31082488.